Return to Trial Database

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-GU20-444 being conducted in.

Icahn School of Medicine at Mount Sinai

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of New Mexico Comprehensive Cancer Center